nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—ADORA2A—ganglion—epilepsy syndrome	0.0186	0.317	CbGeAlD
Regadenoson—ADORA2A—forebrain—epilepsy syndrome	0.00781	0.133	CbGeAlD
Regadenoson—ADORA2A—telencephalon—epilepsy syndrome	0.00718	0.122	CbGeAlD
Regadenoson—ADORA2A—spinal cord—epilepsy syndrome	0.00503	0.0858	CbGeAlD
Regadenoson—ADORA2A—head—epilepsy syndrome	0.00447	0.0762	CbGeAlD
Regadenoson—ADORA2A—nervous system—epilepsy syndrome	0.00424	0.0723	CbGeAlD
Regadenoson—ADORA2A—central nervous system—epilepsy syndrome	0.00408	0.0696	CbGeAlD
Regadenoson—ADORA2A—cerebellum—epilepsy syndrome	0.00399	0.068	CbGeAlD
Regadenoson—Adenosine triphosphate—AFG3L2—epilepsy syndrome	0.00326	0.158	CrCbGaD
Regadenoson—ADORA2A—brain—epilepsy syndrome	0.00324	0.0552	CbGeAlD
Regadenoson—Vidarabine—ADK—epilepsy syndrome	0.00318	0.154	CrCbGaD
Regadenoson—Ribavirin—ADK—epilepsy syndrome	0.00314	0.152	CrCbGaD
Regadenoson—Adenosine—ADK—epilepsy syndrome	0.00254	0.123	CrCbGaD
Regadenoson—Cytarabine—NT5E—epilepsy syndrome	0.00239	0.116	CrCbGaD
Regadenoson—Adenosine monophosphate—ADK—epilepsy syndrome	0.00184	0.0891	CrCbGaD
Regadenoson—Adenosine triphosphate—ADK—epilepsy syndrome	0.00159	0.0772	CrCbGaD
Regadenoson—Adenosine triphosphate—AKT1—epilepsy syndrome	0.000671	0.0326	CrCbGaD
Regadenoson—Adenosine monophosphate—SRC—epilepsy syndrome	0.000662	0.0321	CrCbGaD
Regadenoson—Clofarabine—ABCG2—epilepsy syndrome	0.000577	0.028	CrCbGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—ADRA2A—epilepsy syndrome	0.000461	0.00194	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FYN—epilepsy syndrome	0.000458	0.00193	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MEF2C—epilepsy syndrome	0.000456	0.00192	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—HRH3—epilepsy syndrome	0.000453	0.00191	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—OPRM1—epilepsy syndrome	0.000446	0.00188	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCR10—epilepsy syndrome	0.000443	0.00187	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL12—epilepsy syndrome	0.000442	0.00186	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—BDKRB2—epilepsy syndrome	0.000442	0.00186	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—HBEGF—epilepsy syndrome	0.000442	0.00186	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—NGF—epilepsy syndrome	0.000436	0.00183	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CNR1—epilepsy syndrome	0.000434	0.00183	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT3—epilepsy syndrome	0.000434	0.00183	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GRM2—epilepsy syndrome	0.000426	0.0018	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HTR7—epilepsy syndrome	0.000424	0.00178	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CCR3—epilepsy syndrome	0.000421	0.00178	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—NPY—epilepsy syndrome	0.000411	0.00173	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CRH—epilepsy syndrome	0.000396	0.00167	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CCL3—epilepsy syndrome	0.000396	0.00167	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—OXT—epilepsy syndrome	0.000396	0.00167	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CXCL2—epilepsy syndrome	0.000396	0.00167	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—TSC2—epilepsy syndrome	0.000394	0.00166	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GRM2—epilepsy syndrome	0.000387	0.00163	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—SSTR3—epilepsy syndrome	0.000386	0.00162	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ARHGEF9—epilepsy syndrome	0.00037	0.00156	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—NPY2R—epilepsy syndrome	0.00037	0.00156	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCR9—epilepsy syndrome	0.00037	0.00156	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—SSTR1—epilepsy syndrome	0.00037	0.00156	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCR8—epilepsy syndrome	0.00037	0.00156	CbGpPWpGaD
Regadenoson—ADORA2A—Circadian rythm related genes—NOS2—epilepsy syndrome	0.000366	0.00154	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GRM4—epilepsy syndrome	0.000362	0.00153	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GRM3—epilepsy syndrome	0.000362	0.00153	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6ST—epilepsy syndrome	0.000362	0.00153	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—SST—epilepsy syndrome	0.000358	0.00151	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CCR2—epilepsy syndrome	0.000358	0.00151	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AVP—epilepsy syndrome	0.000357	0.0015	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—SSTR2—epilepsy syndrome	0.000356	0.0015	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—CCR5—epilepsy syndrome	0.000354	0.00149	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—FYN—epilepsy syndrome	0.000353	0.00148	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—ADRA2A—epilepsy syndrome	0.000351	0.00148	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—MEF2C—epilepsy syndrome	0.000351	0.00148	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—SSTR3—epilepsy syndrome	0.00035	0.00147	CbGpPWpGaD
Regadenoson—ADORA2A—GPCRs, Class A Rhodopsin-like—HTR2A—epilepsy syndrome	0.000346	0.00146	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRDM4—epilepsy syndrome	0.000345	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRICKLE1—epilepsy syndrome	0.000345	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GRM8—epilepsy syndrome	0.000344	0.00145	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—CXCL12—epilepsy syndrome	0.000337	0.00142	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—BDKRB2—epilepsy syndrome	0.000337	0.00142	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ARHGEF9—epilepsy syndrome	0.000336	0.00141	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—NPY2R—epilepsy syndrome	0.000336	0.00141	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—SSTR1—epilepsy syndrome	0.000336	0.00141	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCR8—epilepsy syndrome	0.000336	0.00141	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCR9—epilepsy syndrome	0.000336	0.00141	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—NGF—epilepsy syndrome	0.000335	0.00141	CbGpPWpGaD
Regadenoson—Cladribine—ABCG2—epilepsy syndrome	0.000331	0.0161	CrCbGaD
Regadenoson—ADORA2A—GPCR ligand binding—CNR1—epilepsy syndrome	0.000331	0.00139	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GRM4—epilepsy syndrome	0.000329	0.00139	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GRM3—epilepsy syndrome	0.000329	0.00139	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—OPRD1—epilepsy syndrome	0.000328	0.00138	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—SSTR2—epilepsy syndrome	0.000323	0.00136	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—HTR7—epilepsy syndrome	0.000323	0.00136	CbGpPWpGaD
Regadenoson—Adenosine triphosphate—ABCC2—epilepsy syndrome	0.000319	0.0155	CrCbGaD
Regadenoson—Headache—Levetiracetam—epilepsy syndrome	0.000317	0.000463	CcSEcCtD
Regadenoson—Erythema—Gabapentin—epilepsy syndrome	0.000316	0.000463	CcSEcCtD
Regadenoson—Angioedema—Pregabalin—epilepsy syndrome	0.000315	0.000461	CcSEcCtD
Regadenoson—Hypersensitivity—Clonazepam—epilepsy syndrome	0.000315	0.000461	CcSEcCtD
Regadenoson—Dizziness—Vigabatrin—epilepsy syndrome	0.000314	0.00046	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—GRM1—epilepsy syndrome	0.000314	0.00132	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCR7—epilepsy syndrome	0.000314	0.00132	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CHRM1—epilepsy syndrome	0.000314	0.00132	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PDYN—epilepsy syndrome	0.000314	0.00132	CbGpPWpGaD
Regadenoson—Hypersensitivity—Phenytoin—epilepsy syndrome	0.000313	0.000458	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GRM8—epilepsy syndrome	0.000312	0.00131	CbGpPWpGaD
Regadenoson—Anaphylactic shock—Valproic Acid—epilepsy syndrome	0.000311	0.000455	CcSEcCtD
Regadenoson—Urticaria—Lamotrigine—epilepsy syndrome	0.000311	0.000455	CcSEcCtD
Regadenoson—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	0.000311	0.000455	CcSEcCtD
Regadenoson—Bradycardia—Topiramate—epilepsy syndrome	0.000311	0.000455	CcSEcCtD
Regadenoson—Malaise—Pregabalin—epilepsy syndrome	0.000311	0.000455	CcSEcCtD
Regadenoson—Nausea—Propofol—epilepsy syndrome	0.000311	0.000455	CcSEcCtD
Regadenoson—Vomiting—Fosphenytoin—epilepsy syndrome	0.00031	0.000454	CcSEcCtD
Regadenoson—Diarrhoea—Felbamate—epilepsy syndrome	0.00031	0.000454	CcSEcCtD
Regadenoson—Abdominal pain—Lamotrigine—epilepsy syndrome	0.00031	0.000453	CcSEcCtD
Regadenoson—Dysgeusia—Gabapentin—epilepsy syndrome	0.000309	0.000453	CcSEcCtD
Regadenoson—Dizziness—Diazepam—epilepsy syndrome	0.000309	0.000453	CcSEcCtD
Regadenoson—Syncope—Pregabalin—epilepsy syndrome	0.000309	0.000452	CcSEcCtD
Regadenoson—Rash—Fosphenytoin—epilepsy syndrome	0.000307	0.00045	CcSEcCtD
Regadenoson—Dermatitis—Fosphenytoin—epilepsy syndrome	0.000307	0.00045	CcSEcCtD
Regadenoson—Asthenia—Clonazepam—epilepsy syndrome	0.000307	0.000449	CcSEcCtD
Regadenoson—Headache—Fosphenytoin—epilepsy syndrome	0.000305	0.000447	CcSEcCtD
Regadenoson—Nervous system disorder—Valproic Acid—epilepsy syndrome	0.000305	0.000447	CcSEcCtD
Regadenoson—Palpitations—Pregabalin—epilepsy syndrome	0.000305	0.000446	CcSEcCtD
Regadenoson—Asthenia—Phenytoin—epilepsy syndrome	0.000305	0.000446	CcSEcCtD
Regadenoson—Nausea—Midazolam—epilepsy syndrome	0.000304	0.000445	CcSEcCtD
Regadenoson—Hypoaesthesia—Topiramate—epilepsy syndrome	0.000304	0.000445	CcSEcCtD
Regadenoson—Tachycardia—Valproic Acid—epilepsy syndrome	0.000304	0.000444	CcSEcCtD
Regadenoson—Diarrhoea—Zonisamide—epilepsy syndrome	0.000303	0.000444	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—epilepsy syndrome	0.000303	0.00128	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—TSC2—epilepsy syndrome	0.000303	0.00128	CbGpPWpGaD
Regadenoson—Loss of consciousness—Pregabalin—epilepsy syndrome	0.000303	0.000443	CcSEcCtD
Regadenoson—Asthenia—Oxcarbazepine—epilepsy syndrome	0.000303	0.000443	CcSEcCtD
Regadenoson—Vomiting—Vigabatrin—epilepsy syndrome	0.000302	0.000442	CcSEcCtD
Regadenoson—Skin disorder—Valproic Acid—epilepsy syndrome	0.000302	0.000442	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—ACKR4—epilepsy syndrome	0.000302	0.00127	CbGpPWpGaD
Regadenoson—Hyperhidrosis—Valproic Acid—epilepsy syndrome	0.000301	0.00044	CcSEcCtD
Regadenoson—Cough—Pregabalin—epilepsy syndrome	0.000301	0.00044	CcSEcCtD
Regadenoson—Connective tissue disorder—Topiramate—epilepsy syndrome	0.0003	0.000439	CcSEcCtD
Regadenoson—Nausea—Levetiracetam—epilepsy syndrome	0.0003	0.000439	CcSEcCtD
Regadenoson—Rash—Vigabatrin—epilepsy syndrome	0.0003	0.000439	CcSEcCtD
Regadenoson—Dizziness—Felbamate—epilepsy syndrome	0.0003	0.000438	CcSEcCtD
Regadenoson—Dermatitis—Vigabatrin—epilepsy syndrome	0.000299	0.000438	CcSEcCtD
Regadenoson—Convulsion—Pregabalin—epilepsy syndrome	0.000299	0.000437	CcSEcCtD
Regadenoson—Hypersensitivity—Carbamazepine—epilepsy syndrome	0.000298	0.000437	CcSEcCtD
Regadenoson—Vision blurred—Gabapentin—epilepsy syndrome	0.000298	0.000436	CcSEcCtD
Regadenoson—Headache—Vigabatrin—epilepsy syndrome	0.000298	0.000436	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GNAO1—epilepsy syndrome	0.000298	0.00125	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—OPRD1—epilepsy syndrome	0.000298	0.00125	CbGpPWpGaD
Regadenoson—Hypertension—Pregabalin—epilepsy syndrome	0.000298	0.000435	CcSEcCtD
Regadenoson—Vomiting—Diazepam—epilepsy syndrome	0.000298	0.000435	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—epilepsy syndrome	0.000297	0.00125	CbGpPWpGaD
Regadenoson—Tremor—Gabapentin—epilepsy syndrome	0.000296	0.000433	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—GAL—epilepsy syndrome	0.000295	0.00124	CbGpPWpGaD
Regadenoson—Rash—Diazepam—epilepsy syndrome	0.000295	0.000432	CcSEcCtD
Regadenoson—Dermatitis—Diazepam—epilepsy syndrome	0.000295	0.000431	CcSEcCtD
Regadenoson—Chest pain—Pregabalin—epilepsy syndrome	0.000293	0.000429	CcSEcCtD
Regadenoson—Myalgia—Pregabalin—epilepsy syndrome	0.000293	0.000429	CcSEcCtD
Regadenoson—Arthralgia—Pregabalin—epilepsy syndrome	0.000293	0.000429	CcSEcCtD
Regadenoson—Ill-defined disorder—Gabapentin—epilepsy syndrome	0.000293	0.000429	CcSEcCtD
Regadenoson—Dizziness—Zonisamide—epilepsy syndrome	0.000293	0.000429	CcSEcCtD
Regadenoson—Headache—Diazepam—epilepsy syndrome	0.000293	0.000429	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGF2—epilepsy syndrome	0.000293	0.00123	CbGpPWpGaD
Regadenoson—Anxiety—Pregabalin—epilepsy syndrome	0.000292	0.000428	CcSEcCtD
Regadenoson—Diarrhoea—Clonazepam—epilepsy syndrome	0.000292	0.000428	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—CHRM3—epilepsy syndrome	0.000292	0.00123	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—GRM5—epilepsy syndrome	0.000292	0.00123	CbGpPWpGaD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	0.000291	0.000426	CcSEcCtD
Regadenoson—Hypotension—Valproic Acid—epilepsy syndrome	0.000291	0.000425	CcSEcCtD
Regadenoson—Asthenia—Carbamazepine—epilepsy syndrome	0.000291	0.000425	CcSEcCtD
Regadenoson—Diarrhoea—Phenytoin—epilepsy syndrome	0.00029	0.000425	CcSEcCtD
Regadenoson—Discomfort—Pregabalin—epilepsy syndrome	0.00029	0.000424	CcSEcCtD
Regadenoson—Nausea—Fosphenytoin—epilepsy syndrome	0.00029	0.000424	CcSEcCtD
Regadenoson—Diarrhoea—Oxcarbazepine—epilepsy syndrome	0.000289	0.000423	CcSEcCtD
Regadenoson—Angioedema—Gabapentin—epilepsy syndrome	0.000289	0.000423	CcSEcCtD
Regadenoson—Hypersensitivity—Lamotrigine—epilepsy syndrome	0.000288	0.000422	CcSEcCtD
Regadenoson—Vomiting—Felbamate—epilepsy syndrome	0.000288	0.000421	CcSEcCtD
Regadenoson—Rash—Felbamate—epilepsy syndrome	0.000286	0.000418	CcSEcCtD
Regadenoson—Eye disorder—Topiramate—epilepsy syndrome	0.000285	0.000418	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—PDYN—epilepsy syndrome	0.000285	0.0012	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCR7—epilepsy syndrome	0.000285	0.0012	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GRM1—epilepsy syndrome	0.000285	0.0012	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CHRM1—epilepsy syndrome	0.000285	0.0012	CbGpPWpGaD
Regadenoson—Dermatitis—Felbamate—epilepsy syndrome	0.000285	0.000418	CcSEcCtD
Regadenoson—Malaise—Gabapentin—epilepsy syndrome	0.000285	0.000417	CcSEcCtD
Regadenoson—Tinnitus—Topiramate—epilepsy syndrome	0.000285	0.000417	CcSEcCtD
Regadenoson—Headache—Felbamate—epilepsy syndrome	0.000284	0.000415	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	0.000283	0.000415	CcSEcCtD
Regadenoson—Flushing—Topiramate—epilepsy syndrome	0.000283	0.000415	CcSEcCtD
Regadenoson—Cardiac disorder—Topiramate—epilepsy syndrome	0.000283	0.000415	CcSEcCtD
Regadenoson—Syncope—Gabapentin—epilepsy syndrome	0.000283	0.000415	CcSEcCtD
Regadenoson—Dizziness—Clonazepam—epilepsy syndrome	0.000283	0.000414	CcSEcCtD
Regadenoson—Nausea—Vigabatrin—epilepsy syndrome	0.000282	0.000413	CcSEcCtD
Regadenoson—Vomiting—Zonisamide—epilepsy syndrome	0.000282	0.000413	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGT—epilepsy syndrome	0.000282	0.00119	CbGpPWpGaD
Regadenoson—Insomnia—Valproic Acid—epilepsy syndrome	0.000281	0.000412	CcSEcCtD
Regadenoson—Anaphylactic shock—Pregabalin—epilepsy syndrome	0.000281	0.000412	CcSEcCtD
Regadenoson—Asthenia—Lamotrigine—epilepsy syndrome	0.000281	0.000411	CcSEcCtD
Regadenoson—Dizziness—Phenytoin—epilepsy syndrome	0.000281	0.000411	CcSEcCtD
Regadenoson—Rash—Zonisamide—epilepsy syndrome	0.00028	0.000409	CcSEcCtD
Regadenoson—Paraesthesia—Valproic Acid—epilepsy syndrome	0.000279	0.000409	CcSEcCtD
Regadenoson—Palpitations—Gabapentin—epilepsy syndrome	0.000279	0.000409	CcSEcCtD
Regadenoson—Dermatitis—Zonisamide—epilepsy syndrome	0.000279	0.000409	CcSEcCtD
Regadenoson—Dizziness—Oxcarbazepine—epilepsy syndrome	0.000279	0.000409	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—IL6ST—epilepsy syndrome	0.000279	0.00117	CbGpPWpGaD
Regadenoson—Nausea—Diazepam—epilepsy syndrome	0.000278	0.000407	CcSEcCtD
Regadenoson—Loss of consciousness—Gabapentin—epilepsy syndrome	0.000278	0.000407	CcSEcCtD
Regadenoson—Headache—Zonisamide—epilepsy syndrome	0.000278	0.000406	CcSEcCtD
Regadenoson—Dyspnoea—Valproic Acid—epilepsy syndrome	0.000277	0.000406	CcSEcCtD
Regadenoson—Diarrhoea—Carbamazepine—epilepsy syndrome	0.000277	0.000406	CcSEcCtD
Regadenoson—Angiopathy—Topiramate—epilepsy syndrome	0.000277	0.000406	CcSEcCtD
Regadenoson—Shock—Pregabalin—epilepsy syndrome	0.000277	0.000405	CcSEcCtD
Regadenoson—Somnolence—Valproic Acid—epilepsy syndrome	0.000277	0.000405	CcSEcCtD
Regadenoson—Immune system disorder—Topiramate—epilepsy syndrome	0.000276	0.000404	CcSEcCtD
Regadenoson—Nervous system disorder—Pregabalin—epilepsy syndrome	0.000276	0.000404	CcSEcCtD
Regadenoson—Cough—Gabapentin—epilepsy syndrome	0.000276	0.000404	CcSEcCtD
Regadenoson—Mediastinal disorder—Topiramate—epilepsy syndrome	0.000275	0.000403	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—BDKRB1—epilepsy syndrome	0.000275	0.00116	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CHRM2—epilepsy syndrome	0.000275	0.00116	CbGpPWpGaD
Regadenoson—Tachycardia—Pregabalin—epilepsy syndrome	0.000275	0.000402	CcSEcCtD
Regadenoson—Convulsion—Gabapentin—epilepsy syndrome	0.000274	0.000401	CcSEcCtD
Regadenoson—Skin disorder—Pregabalin—epilepsy syndrome	0.000273	0.0004	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—SSTR5—epilepsy syndrome	0.000273	0.00115	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SSTR4—epilepsy syndrome	0.000273	0.00115	CbGpPWpGaD
Regadenoson—Hypertension—Gabapentin—epilepsy syndrome	0.000273	0.000399	CcSEcCtD
Regadenoson—Hyperhidrosis—Pregabalin—epilepsy syndrome	0.000272	0.000398	CcSEcCtD
Regadenoson—Vomiting—Clonazepam—epilepsy syndrome	0.000272	0.000398	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—AVP—epilepsy syndrome	0.000272	0.00114	CbGpPWpGaD
Regadenoson—Vomiting—Phenytoin—epilepsy syndrome	0.00027	0.000395	CcSEcCtD
Regadenoson—Rash—Clonazepam—epilepsy syndrome	0.000269	0.000394	CcSEcCtD
Regadenoson—Dermatitis—Clonazepam—epilepsy syndrome	0.000269	0.000394	CcSEcCtD
Regadenoson—Myalgia—Gabapentin—epilepsy syndrome	0.000269	0.000394	CcSEcCtD
Regadenoson—Arthralgia—Gabapentin—epilepsy syndrome	0.000269	0.000394	CcSEcCtD
Regadenoson—Chest pain—Gabapentin—epilepsy syndrome	0.000269	0.000394	CcSEcCtD
Regadenoson—Nausea—Felbamate—epilepsy syndrome	0.000269	0.000394	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	0.000269	0.000393	CcSEcCtD
Regadenoson—Vomiting—Oxcarbazepine—epilepsy syndrome	0.000268	0.000393	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GAL—epilepsy syndrome	0.000268	0.00113	CbGpPWpGaD
Regadenoson—Anxiety—Gabapentin—epilepsy syndrome	0.000268	0.000392	CcSEcCtD
Regadenoson—Dizziness—Carbamazepine—epilepsy syndrome	0.000268	0.000392	CcSEcCtD
Regadenoson—Diarrhoea—Lamotrigine—epilepsy syndrome	0.000268	0.000392	CcSEcCtD
Regadenoson—Headache—Clonazepam—epilepsy syndrome	0.000268	0.000392	CcSEcCtD
Regadenoson—Rash—Phenytoin—epilepsy syndrome	0.000268	0.000392	CcSEcCtD
Regadenoson—Mental disorder—Topiramate—epilepsy syndrome	0.000268	0.000392	CcSEcCtD
Regadenoson—Dermatitis—Phenytoin—epilepsy syndrome	0.000267	0.000391	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—GABBR1—epilepsy syndrome	0.000267	0.00113	CbGpPWpGaD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	0.000267	0.000391	CcSEcCtD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—MTOR—epilepsy syndrome	0.000267	0.00112	CbGpPWpGaD
Regadenoson—Rash—Oxcarbazepine—epilepsy syndrome	0.000266	0.00039	CcSEcCtD
Regadenoson—Pain—Valproic Acid—epilepsy syndrome	0.000266	0.000389	CcSEcCtD
Regadenoson—Dermatitis—Oxcarbazepine—epilepsy syndrome	0.000266	0.000389	CcSEcCtD
Regadenoson—Headache—Phenytoin—epilepsy syndrome	0.000266	0.000389	CcSEcCtD
Regadenoson—Erythema—Topiramate—epilepsy syndrome	0.000266	0.000389	CcSEcCtD
Regadenoson—Discomfort—Gabapentin—epilepsy syndrome	0.000266	0.000389	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—CHRM3—epilepsy syndrome	0.000265	0.00112	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—GRM5—epilepsy syndrome	0.000265	0.00112	CbGpPWpGaD
Regadenoson—Headache—Oxcarbazepine—epilepsy syndrome	0.000264	0.000387	CcSEcCtD
Regadenoson—Nausea—Zonisamide—epilepsy syndrome	0.000263	0.000385	CcSEcCtD
Regadenoson—Hypotension—Pregabalin—epilepsy syndrome	0.000263	0.000385	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CCR10—epilepsy syndrome	0.000262	0.0011	CbGpPWpGaD
Regadenoson—Dysgeusia—Topiramate—epilepsy syndrome	0.00026	0.000381	CcSEcCtD
Regadenoson—Dizziness—Lamotrigine—epilepsy syndrome	0.000259	0.000379	CcSEcCtD
Regadenoson—Anaphylactic shock—Gabapentin—epilepsy syndrome	0.000258	0.000377	CcSEcCtD
Regadenoson—Vomiting—Carbamazepine—epilepsy syndrome	0.000258	0.000377	CcSEcCtD
Regadenoson—Feeling abnormal—Valproic Acid—epilepsy syndrome	0.000256	0.000375	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	0.000256	0.000375	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—HRH3—epilepsy syndrome	0.000256	0.00108	CbGpPWpGaD
Regadenoson—Rash—Carbamazepine—epilepsy syndrome	0.000255	0.000374	CcSEcCtD
Regadenoson—Dermatitis—Carbamazepine—epilepsy syndrome	0.000255	0.000373	CcSEcCtD
Regadenoson—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	0.000254	0.000372	CcSEcCtD
Regadenoson—Insomnia—Pregabalin—epilepsy syndrome	0.000254	0.000372	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—CX3CR1—epilepsy syndrome	0.000254	0.00107	CbGpPWpGaD
Regadenoson—Nausea—Clonazepam—epilepsy syndrome	0.000254	0.000371	CcSEcCtD
Regadenoson—Headache—Carbamazepine—epilepsy syndrome	0.000254	0.000371	CcSEcCtD
Regadenoson—Shock—Gabapentin—epilepsy syndrome	0.000254	0.000371	CcSEcCtD
Regadenoson—Nervous system disorder—Gabapentin—epilepsy syndrome	0.000253	0.00037	CcSEcCtD
Regadenoson—Paraesthesia—Pregabalin—epilepsy syndrome	0.000253	0.00037	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—OPRM1—epilepsy syndrome	0.000252	0.00106	CbGpPWpGaD
Regadenoson—Nausea—Phenytoin—epilepsy syndrome	0.000252	0.000369	CcSEcCtD
Regadenoson—Tachycardia—Gabapentin—epilepsy syndrome	0.000252	0.000368	CcSEcCtD
Regadenoson—Dyspnoea—Pregabalin—epilepsy syndrome	0.000251	0.000367	CcSEcCtD
Regadenoson—Nausea—Oxcarbazepine—epilepsy syndrome	0.000251	0.000367	CcSEcCtD
Regadenoson—Vision blurred—Topiramate—epilepsy syndrome	0.000251	0.000367	CcSEcCtD
Regadenoson—Skin disorder—Gabapentin—epilepsy syndrome	0.000251	0.000367	CcSEcCtD
Regadenoson—Somnolence—Pregabalin—epilepsy syndrome	0.00025	0.000366	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—BDKRB1—epilepsy syndrome	0.000249	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CHRM2—epilepsy syndrome	0.000249	0.00105	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CX3CL1—epilepsy syndrome	0.000249	0.00105	CbGpPWpGaD
Regadenoson—Hyperhidrosis—Gabapentin—epilepsy syndrome	0.000249	0.000365	CcSEcCtD
Regadenoson—Tremor—Topiramate—epilepsy syndrome	0.000249	0.000365	CcSEcCtD
Regadenoson—Vomiting—Lamotrigine—epilepsy syndrome	0.000249	0.000364	CcSEcCtD
Regadenoson—Urticaria—Valproic Acid—epilepsy syndrome	0.000247	0.000362	CcSEcCtD
Regadenoson—Rash—Lamotrigine—epilepsy syndrome	0.000247	0.000361	CcSEcCtD
Regadenoson—Ill-defined disorder—Topiramate—epilepsy syndrome	0.000247	0.000361	CcSEcCtD
Regadenoson—Dermatitis—Lamotrigine—epilepsy syndrome	0.000247	0.000361	CcSEcCtD
Regadenoson—Abdominal pain—Valproic Acid—epilepsy syndrome	0.000246	0.00036	CcSEcCtD
Regadenoson—Headache—Lamotrigine—epilepsy syndrome	0.000245	0.000359	CcSEcCtD
Regadenoson—ADORA2A—Circadian rythm related genes—JUN—epilepsy syndrome	0.000243	0.00102	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	0.000243	0.000355	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—GABBR1—epilepsy syndrome	0.000243	0.00102	CbGpPWpGaD
Regadenoson—Hypotension—Gabapentin—epilepsy syndrome	0.000241	0.000353	CcSEcCtD
Regadenoson—Nausea—Carbamazepine—epilepsy syndrome	0.000241	0.000352	CcSEcCtD
Regadenoson—Pain—Pregabalin—epilepsy syndrome	0.000241	0.000352	CcSEcCtD
Regadenoson—Malaise—Topiramate—epilepsy syndrome	0.00024	0.000351	CcSEcCtD
Regadenoson—Syncope—Topiramate—epilepsy syndrome	0.000238	0.000349	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—CCR3—epilepsy syndrome	0.000238	0.001	CbGpPWpGaD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—POMC—epilepsy syndrome	0.000237	0.000998	CbGpPWpGaD
Regadenoson—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	0.000235	0.000344	CcSEcCtD
Regadenoson—Palpitations—Topiramate—epilepsy syndrome	0.000235	0.000344	CcSEcCtD
Regadenoson—Loss of consciousness—Topiramate—epilepsy syndrome	0.000234	0.000342	CcSEcCtD
Regadenoson—Insomnia—Gabapentin—epilepsy syndrome	0.000233	0.000341	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—HRH3—epilepsy syndrome	0.000233	0.00098	CbGpPWpGaD
Regadenoson—Nausea—Lamotrigine—epilepsy syndrome	0.000233	0.00034	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—NPY—epilepsy syndrome	0.000232	0.000978	CbGpPWpGaD
Regadenoson—Cough—Topiramate—epilepsy syndrome	0.000232	0.00034	CcSEcCtD
Regadenoson—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—epilepsy syndrome	0.000232	0.000977	CbGpPWpGaD
Regadenoson—Feeling abnormal—Pregabalin—epilepsy syndrome	0.000232	0.000339	CcSEcCtD
Regadenoson—Paraesthesia—Gabapentin—epilepsy syndrome	0.000232	0.000339	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—CCR5—epilepsy syndrome	0.000231	0.000973	CbGpPWpGaD
Regadenoson—Convulsion—Topiramate—epilepsy syndrome	0.00023	0.000337	CcSEcCtD
Regadenoson—Gastrointestinal pain—Pregabalin—epilepsy syndrome	0.00023	0.000337	CcSEcCtD
Regadenoson—Dyspnoea—Gabapentin—epilepsy syndrome	0.00023	0.000337	CcSEcCtD
Regadenoson—Hypertension—Topiramate—epilepsy syndrome	0.00023	0.000336	CcSEcCtD
Regadenoson—Somnolence—Gabapentin—epilepsy syndrome	0.000229	0.000336	CcSEcCtD
Regadenoson—Hypersensitivity—Valproic Acid—epilepsy syndrome	0.000229	0.000335	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—OPRM1—epilepsy syndrome	0.000229	0.000965	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRM2—epilepsy syndrome	0.000229	0.000963	CbGpPWpGaD
Regadenoson—Arthralgia—Topiramate—epilepsy syndrome	0.000226	0.000331	CcSEcCtD
Regadenoson—Myalgia—Topiramate—epilepsy syndrome	0.000226	0.000331	CcSEcCtD
Regadenoson—Chest pain—Topiramate—epilepsy syndrome	0.000226	0.000331	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—HTR2A—epilepsy syndrome	0.000226	0.000952	CbGpPWpGaD
Regadenoson—Anxiety—Topiramate—epilepsy syndrome	0.000226	0.00033	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—FGF2—epilepsy syndrome	0.000225	0.000949	CbGpPWpGaD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	0.000225	0.000329	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—CRH—epilepsy syndrome	0.000224	0.000943	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL2—epilepsy syndrome	0.000224	0.000943	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—OXT—epilepsy syndrome	0.000224	0.000943	CbGpPWpGaD
Regadenoson—Discomfort—Topiramate—epilepsy syndrome	0.000224	0.000327	CcSEcCtD
Regadenoson—Urticaria—Pregabalin—epilepsy syndrome	0.000223	0.000327	CcSEcCtD
Regadenoson—Asthenia—Valproic Acid—epilepsy syndrome	0.000223	0.000327	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	0.000223	0.000326	CcSEcCtD
Regadenoson—Abdominal pain—Pregabalin—epilepsy syndrome	0.000222	0.000325	CcSEcCtD
Regadenoson—Pain—Gabapentin—epilepsy syndrome	0.000221	0.000323	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—CCR3—epilepsy syndrome	0.000216	0.000911	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—AGT—epilepsy syndrome	0.000214	0.000903	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—epilepsy syndrome	0.000214	0.0009	CbGpPWpGaD
Regadenoson—Shock—Topiramate—epilepsy syndrome	0.000213	0.000312	CcSEcCtD
Regadenoson—Diarrhoea—Valproic Acid—epilepsy syndrome	0.000213	0.000312	CcSEcCtD
Regadenoson—Nervous system disorder—Topiramate—epilepsy syndrome	0.000213	0.000311	CcSEcCtD
Regadenoson—Feeling abnormal—Gabapentin—epilepsy syndrome	0.000213	0.000311	CcSEcCtD
Regadenoson—Tachycardia—Topiramate—epilepsy syndrome	0.000212	0.00031	CcSEcCtD
Regadenoson—Gastrointestinal pain—Gabapentin—epilepsy syndrome	0.000211	0.000309	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—NPY—epilepsy syndrome	0.000211	0.000888	CbGpPWpGaD
Regadenoson—Skin disorder—Topiramate—epilepsy syndrome	0.000211	0.000308	CcSEcCtD
Regadenoson—Hyperhidrosis—Topiramate—epilepsy syndrome	0.00021	0.000307	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—RELA—epilepsy syndrome	0.000209	0.000881	CbGpPWpGaD
Regadenoson—Hypersensitivity—Pregabalin—epilepsy syndrome	0.000207	0.000303	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—SSTR3—epilepsy syndrome	0.000207	0.000871	CbGpPWpGaD
Regadenoson—Dizziness—Valproic Acid—epilepsy syndrome	0.000206	0.000301	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—MTOR—epilepsy syndrome	0.000205	0.000864	CbGpPWpGaD
Regadenoson—Urticaria—Gabapentin—epilepsy syndrome	0.000205	0.0003	CcSEcCtD
Regadenoson—Abdominal pain—Gabapentin—epilepsy syndrome	0.000204	0.000298	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—OXT—epilepsy syndrome	0.000203	0.000856	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL2—epilepsy syndrome	0.000203	0.000856	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCL3—epilepsy syndrome	0.000203	0.000856	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CRH—epilepsy syndrome	0.000203	0.000856	CbGpPWpGaD
Regadenoson—Hypotension—Topiramate—epilepsy syndrome	0.000203	0.000297	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—SST—epilepsy syndrome	0.000203	0.000853	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCR2—epilepsy syndrome	0.000203	0.000853	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ST3GAL3—epilepsy syndrome	0.000202	0.000852	CbGpPWpGaD
Regadenoson—Asthenia—Pregabalin—epilepsy syndrome	0.000202	0.000295	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—ARHGEF9—epilepsy syndrome	0.000198	0.000835	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NPY2R—epilepsy syndrome	0.000198	0.000835	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCR8—epilepsy syndrome	0.000198	0.000835	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SSTR1—epilepsy syndrome	0.000198	0.000835	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCR9—epilepsy syndrome	0.000198	0.000835	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—ADRA2A—epilepsy syndrome	0.000198	0.000835	CbGpPWpGaD
Regadenoson—Vomiting—Valproic Acid—epilepsy syndrome	0.000198	0.00029	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	0.000198	0.000289	CcSEcCtD
Regadenoson—Insomnia—Topiramate—epilepsy syndrome	0.000196	0.000287	CcSEcCtD
Regadenoson—Rash—Valproic Acid—epilepsy syndrome	0.000196	0.000287	CcSEcCtD
Regadenoson—Dermatitis—Valproic Acid—epilepsy syndrome	0.000196	0.000287	CcSEcCtD
Regadenoson—Headache—Valproic Acid—epilepsy syndrome	0.000195	0.000285	CcSEcCtD
Regadenoson—Paraesthesia—Topiramate—epilepsy syndrome	0.000195	0.000285	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—GRM4—epilepsy syndrome	0.000194	0.000819	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRM3—epilepsy syndrome	0.000194	0.000819	CbGpPWpGaD
Regadenoson—Dyspnoea—Topiramate—epilepsy syndrome	0.000193	0.000283	CcSEcCtD
Regadenoson—Somnolence—Topiramate—epilepsy syndrome	0.000193	0.000282	CcSEcCtD
Regadenoson—Diarrhoea—Pregabalin—epilepsy syndrome	0.000192	0.000282	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—DUSP4—epilepsy syndrome	0.000191	0.000804	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SSTR2—epilepsy syndrome	0.000191	0.000804	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—BDKRB2—epilepsy syndrome	0.00019	0.000802	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CXCL12—epilepsy syndrome	0.00019	0.000802	CbGpPWpGaD
Regadenoson—Hypersensitivity—Gabapentin—epilepsy syndrome	0.00019	0.000278	CcSEcCtD
Regadenoson—ADORA2A—Signaling by NGF—CASP3—epilepsy syndrome	0.000189	0.000794	CbGpPWpGaD
Regadenoson—Gastrointestinal disorder—Topiramate—epilepsy syndrome	0.000187	0.000274	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—CNR1—epilepsy syndrome	0.000187	0.000787	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PLCB1—epilepsy syndrome	0.000186	0.000784	CbGpPWpGaD
Regadenoson—Dizziness—Pregabalin—epilepsy syndrome	0.000186	0.000272	CcSEcCtD
Regadenoson—Pain—Topiramate—epilepsy syndrome	0.000186	0.000272	CcSEcCtD
Regadenoson—Asthenia—Gabapentin—epilepsy syndrome	0.000185	0.000271	CcSEcCtD
Regadenoson—Nausea—Valproic Acid—epilepsy syndrome	0.000185	0.00027	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—PGF—epilepsy syndrome	0.000184	0.000776	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRM8—epilepsy syndrome	0.000184	0.000776	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—SST—epilepsy syndrome	0.000184	0.000775	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCR2—epilepsy syndrome	0.000184	0.000775	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—HTR7—epilepsy syndrome	0.000182	0.000768	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR ligand binding—POMC—epilepsy syndrome	0.00018	0.00076	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—ADRA2A—epilepsy syndrome	0.00018	0.000758	CbGpPWpGaD
Regadenoson—Vomiting—Pregabalin—epilepsy syndrome	0.000179	0.000262	CcSEcCtD
Regadenoson—Feeling abnormal—Topiramate—epilepsy syndrome	0.000179	0.000262	CcSEcCtD
Regadenoson—Gastrointestinal pain—Topiramate—epilepsy syndrome	0.000177	0.00026	CcSEcCtD
Regadenoson—Rash—Pregabalin—epilepsy syndrome	0.000177	0.00026	CcSEcCtD
Regadenoson—Dermatitis—Pregabalin—epilepsy syndrome	0.000177	0.000259	CcSEcCtD
Regadenoson—ADORA2A—GPCR ligand binding—CCL2—epilepsy syndrome	0.000177	0.000744	CbGpPWpGaD
Regadenoson—Diarrhoea—Gabapentin—epilepsy syndrome	0.000176	0.000258	CcSEcCtD
Regadenoson—Headache—Pregabalin—epilepsy syndrome	0.000176	0.000258	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—GNAO1—epilepsy syndrome	0.000176	0.000741	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—OPRD1—epilepsy syndrome	0.000176	0.000741	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT3—epilepsy syndrome	0.000174	0.000732	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—BDKRB2—epilepsy syndrome	0.000173	0.000728	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CXCL12—epilepsy syndrome	0.000173	0.000728	CbGpPWpGaD
Regadenoson—Urticaria—Topiramate—epilepsy syndrome	0.000172	0.000252	CcSEcCtD
Regadenoson—Abdominal pain—Topiramate—epilepsy syndrome	0.000172	0.000251	CcSEcCtD
Regadenoson—Dizziness—Gabapentin—epilepsy syndrome	0.000171	0.00025	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—CNR1—epilepsy syndrome	0.00017	0.000715	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PLCB1—epilepsy syndrome	0.000169	0.000712	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CHRM1—epilepsy syndrome	0.000169	0.00071	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PDYN—epilepsy syndrome	0.000169	0.00071	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCR7—epilepsy syndrome	0.000169	0.00071	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRM1—epilepsy syndrome	0.000169	0.00071	CbGpPWpGaD
Regadenoson—Nausea—Pregabalin—epilepsy syndrome	0.000167	0.000245	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—HTR7—epilepsy syndrome	0.000166	0.000697	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—SRC—epilepsy syndrome	0.000164	0.000692	CbGpPWpGaD
Regadenoson—Vomiting—Gabapentin—epilepsy syndrome	0.000164	0.00024	CcSEcCtD
Regadenoson—Rash—Gabapentin—epilepsy syndrome	0.000163	0.000238	CcSEcCtD
Regadenoson—Dermatitis—Gabapentin—epilepsy syndrome	0.000162	0.000238	CcSEcCtD
Regadenoson—Headache—Gabapentin—epilepsy syndrome	0.000162	0.000236	CcSEcCtD
Regadenoson—ADORA2A—Signaling by GPCR—HBEGF—epilepsy syndrome	0.000161	0.000677	CbGpPWpGaD
Regadenoson—Hypersensitivity—Topiramate—epilepsy syndrome	0.00016	0.000234	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—CDC42—epilepsy syndrome	0.000159	0.000668	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GFAP—epilepsy syndrome	0.000159	0.000668	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GAL—epilepsy syndrome	0.000159	0.000668	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT3—epilepsy syndrome	0.000158	0.000665	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CHRM3—epilepsy syndrome	0.000157	0.00066	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CASP2—epilepsy syndrome	0.000157	0.00066	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—GRM5—epilepsy syndrome	0.000157	0.00066	CbGpPWpGaD
Regadenoson—Asthenia—Topiramate—epilepsy syndrome	0.000156	0.000228	CcSEcCtD
Regadenoson—ADORA2A—GPCR downstream signaling—AVP—epilepsy syndrome	0.000153	0.000646	CbGpPWpGaD
Regadenoson—Nausea—Gabapentin—epilepsy syndrome	0.000153	0.000224	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CX3CR1—epilepsy syndrome	0.00015	0.000633	CbGpPWpGaD
Regadenoson—Diarrhoea—Topiramate—epilepsy syndrome	0.000148	0.000217	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CHRM2—epilepsy syndrome	0.000147	0.000621	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CX3CL1—epilepsy syndrome	0.000147	0.000621	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BDKRB1—epilepsy syndrome	0.000147	0.000621	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CDC42—epilepsy syndrome	0.000144	0.000606	CbGpPWpGaD
Regadenoson—Dizziness—Topiramate—epilepsy syndrome	0.000143	0.00021	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—GABBR1—epilepsy syndrome	0.000143	0.000604	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AVP—epilepsy syndrome	0.000139	0.000587	CbGpPWpGaD
Regadenoson—Vomiting—Topiramate—epilepsy syndrome	0.000138	0.000202	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—HRH3—epilepsy syndrome	0.000137	0.000579	CbGpPWpGaD
Regadenoson—Rash—Topiramate—epilepsy syndrome	0.000137	0.0002	CcSEcCtD
Regadenoson—Dermatitis—Topiramate—epilepsy syndrome	0.000137	0.0002	CcSEcCtD
Regadenoson—Headache—Topiramate—epilepsy syndrome	0.000136	0.000199	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—OPRM1—epilepsy syndrome	0.000135	0.00057	CbGpPWpGaD
Regadenoson—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—epilepsy syndrome	0.000133	0.000559	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—CCR5—epilepsy syndrome	0.000131	0.00055	CbGpPWpGaD
Regadenoson—Nausea—Topiramate—epilepsy syndrome	0.000129	0.000189	CcSEcCtD
Regadenoson—ADORA2A—Signaling Pathways—CCR3—epilepsy syndrome	0.000128	0.000538	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—HTR2A—epilepsy syndrome	0.000128	0.000538	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NPY—epilepsy syndrome	0.000125	0.000524	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ATP2A2—epilepsy syndrome	0.000125	0.000524	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AGT—epilepsy syndrome	0.000121	0.00051	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HSPB1—epilepsy syndrome	0.00012	0.000506	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL2—epilepsy syndrome	0.00012	0.000506	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CRH—epilepsy syndrome	0.00012	0.000506	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCL3—epilepsy syndrome	0.00012	0.000506	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—OXT—epilepsy syndrome	0.00012	0.000506	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCR5—epilepsy syndrome	0.000119	0.000499	CbGpPWpGaD
Regadenoson—Adenosine triphosphate—ABCB1—epilepsy syndrome	0.000117	0.00568	CrCbGaD
Regadenoson—ADORA2A—Signaling by GPCR—HTR2A—epilepsy syndrome	0.000116	0.000488	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—PRKCB—epilepsy syndrome	0.000112	0.000472	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TSC1—epilepsy syndrome	0.000112	0.00047	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PTK2B—epilepsy syndrome	0.000112	0.00047	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AGT—epilepsy syndrome	0.00011	0.000463	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SST—epilepsy syndrome	0.000109	0.000458	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCR2—epilepsy syndrome	0.000109	0.000458	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NTRK2—epilepsy syndrome	0.000109	0.000458	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—DUSP6—epilepsy syndrome	0.000108	0.000454	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADRA2A—epilepsy syndrome	0.000106	0.000448	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PLAT—epilepsy syndrome	0.000106	0.000446	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—BDKRB2—epilepsy syndrome	0.000102	0.00043	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CXCL12—epilepsy syndrome	0.000102	0.00043	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by NGF—AKT1—epilepsy syndrome	0.000102	0.00043	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—POMC—epilepsy syndrome	0.000102	0.00043	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—PRKCB—epilepsy syndrome	0.000102	0.000428	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—IL6ST—epilepsy syndrome	0.000101	0.000427	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JUNB—epilepsy syndrome	0.0001	0.000422	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CNR1—epilepsy syndrome	0.0001	0.000422	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PLCB1—epilepsy syndrome	9.99e-05	0.000421	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HTR7—epilepsy syndrome	9.78e-05	0.000412	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HBEGF—epilepsy syndrome	9.5e-05	0.0004	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT3—epilepsy syndrome	9.32e-05	0.000393	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—POMC—epilepsy syndrome	9.26e-05	0.00039	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—ADAM10—epilepsy syndrome	9.1e-05	0.000383	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—CCL2—epilepsy syndrome	9.06e-05	0.000382	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—S100B—epilepsy syndrome	8.61e-05	0.000363	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SOCS3—epilepsy syndrome	8.53e-05	0.000359	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CDC42—epilepsy syndrome	8.5e-05	0.000358	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AVP—epilepsy syndrome	8.23e-05	0.000347	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HES1—epilepsy syndrome	7.79e-05	0.000328	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FYN—epilepsy syndrome	7.57e-05	0.000319	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—H2AFX—epilepsy syndrome	7.54e-05	0.000318	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MEF2C—epilepsy syndrome	7.53e-05	0.000317	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—YWHAZ—epilepsy syndrome	7.28e-05	0.000307	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—NGF—epilepsy syndrome	7.2e-05	0.000303	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCR5—epilepsy syndrome	7e-05	0.000295	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—HTR2A—epilepsy syndrome	6.85e-05	0.000289	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—TSC2—epilepsy syndrome	6.51e-05	0.000274	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AGT—epilepsy syndrome	6.5e-05	0.000274	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—APOE—epilepsy syndrome	6.37e-05	0.000268	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—KDR—epilepsy syndrome	6.24e-05	0.000263	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—PRKCB—epilepsy syndrome	6.01e-05	0.000253	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—IL6ST—epilepsy syndrome	5.98e-05	0.000252	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—POMC—epilepsy syndrome	5.47e-05	0.00023	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CCL2—epilepsy syndrome	5.35e-05	0.000225	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—FGF2—epilepsy syndrome	4.84e-05	0.000204	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—RELA—epilepsy syndrome	4.49e-05	0.000189	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MTOR—epilepsy syndrome	4.4e-05	0.000185	CbGpPWpGaD
Regadenoson—ADORA2A—GPCR downstream signaling—AKT1—epilepsy syndrome	4.09e-05	0.000172	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—CASP3—epilepsy syndrome	4.05e-05	0.000171	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—JUN—epilepsy syndrome	3.94e-05	0.000166	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—MMP9—epilepsy syndrome	3.83e-05	0.000161	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling by GPCR—AKT1—epilepsy syndrome	3.71e-05	0.000156	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—SRC—epilepsy syndrome	3.53e-05	0.000149	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—VEGFA—epilepsy syndrome	3.44e-05	0.000145	CbGpPWpGaD
Regadenoson—ADORA2A—Signaling Pathways—AKT1—epilepsy syndrome	2.19e-05	9.24e-05	CbGpPWpGaD
